Rohit Adyanthaya, MD
Ophthalmology · Norfolk, VANPI 1710023411
Payments from drug & device makers
Across 193 payments — averaging $842.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$157K
- Regeneron Healthcare Solutions, Inc.$970
- AbbVie$958
- Apellis Pharmaceuticals, Inc.$554
- Notal Vision, Inc.$437
- Endo USA, Inc.$400
- plus $2K from 22 others
What the payments were for
- Consulting fees$96817%
- Speaking & faculty fees$3997%
- Grants$120%
- Food & beverage$4,29874%
- Education$1422%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 11 | $156,990 |
| Regeneron Healthcare Solutions, Inc. | 36 | $970 |
| AbbVie(2 entities) | 53 | $958 |
| Apellis Pharmaceuticals, Inc. | 22 | $554 |
| Notal Vision, Inc. | 3 | $437 |
| Endo USA, Inc. | 1 | $400 |
| Mallinckrodt Hospital Products Inc. | 12 | $391 |
| Thea Pharma Inc. | 1 | $350 |
| Genentech USA, Inc. | 11 | $256 |
| Astellas Pharma US Inc | 9 | $253 |
| Dr.reddy's Laboratories,inc. | 1 | $218 |
| Eyepoint US, Inc. | 1 | $124 |
| NEW World Medical,inc. | 1 | $103 |
| Alimera Sciences, Inc. | 5 | $98 |
| Biotissue Holdings Inc. | 1 | $92 |
| Oyster Point Pharma, Inc. | 4 | $78 |
| Amgen(2 entities) | 3 | $65 |
| Alcon | 3 | $58 |
| Bausch & Lomb Americas Inc. | 3 | $55 |
| ANI Pharmaceuticals, Inc. | 2 | $52 |
| Aerie Pharmaceuticals, Inc. | 3 | $48 |
| Biogen | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $19 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- YUTIQ$124
How this compares
$162,678 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 29 | $32,519 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $15,145 |
| ProlensaBromfenac Sodium | 19 | $9,119 |
| Prednisolone Acetate | 171 | $8,305 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $7,962 |
| Difluprednate | 57 | $5,680 |
| Bromfenac Sodium | 21 | $5,280 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 50 | $4,562 |
| Brimonidine Tartrate | 61 | $2,212 |
| Loteprednol Etabonate | 12 | $1,909 |
| Ketorolac Tromethamine | 50 | $1,754 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 98 | $1,450 |
| Atropine Sulfate | 47 | $1,320 |
| Brinzolamide | 11 | $1,266 |
| Ofloxacin | 101 | $1,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan | $958 | $47,66453 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $19 | $11,02931 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $48 | $7,96214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Norfolk
- Kapil KapoorNorfolk$4.3M
- Elizabeth Yeu-LinNorfolk$2M
- Alan WagnerNorfolk$1.8M
- John SheppardNorfolk$1.2M
- Constance OkekeNorfolk$822K
- Stephen ScoperNorfolk$142K
- Thomas JolyNorfolk$95K
- Albert CheungNorfolk$23K
- Samantha DewundaraNorfolk$19K
- Arielle SpitzeNorfolk$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.